BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8980999)

  • 21. Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms.
    Tonacchera M; Vitti P; Agretti P; Ceccarini G; Perri A; Cavaliere R; Mazzi B; Naccarato AG; Viacava P; Miccoli P; Pinchera A; Chiovato L
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4155-8. PubMed ID: 10566665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathology of the TSH receptor.
    Duprez L; Parma J; Van Sande J; Rodien P; Sabine C; Abramowicz M; Dumont JE; Vassart G
    J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():295-302. PubMed ID: 10698593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas.
    Parma J; Duprez L; Van Sande J; Hermans J; Rocmans P; Van Vliet G; Costagliola S; Rodien P; Dumont JE; Vassart G
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2695-701. PubMed ID: 9253356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyrotropin receptor mutations in hyperfunctioning thyroid adenomas from Brazil.
    Nogueira CR; Kopp P; Arseven OK; Santos CL; Jameson JL; Medeiros-Neto G
    Thyroid; 1999 Nov; 9(11):1063-8. PubMed ID: 10595453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features.
    Arturi F; Capula C; Chiefari E; Filetti S; Russo D
    Exp Clin Endocrinol Diabetes; 1998; 106(3):234-6. PubMed ID: 9710366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5.
    Karges B; Krause G; Homoki J; Debatin KM; de Roux N; Karges W
    J Endocrinol; 2005 Aug; 186(2):377-85. PubMed ID: 16079263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Molecular aspects in the pathogenesis of nodules and adenomas of the thyroid gland].
    Derwahl M
    Schweiz Med Wochenschr; 1994 Sep; 124(37):1613-8. PubMed ID: 7939528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low incidence of the stimulatory G protein alpha-subunit mutations in autonomously functioning thyroid adenomas in Japan.
    Tanaka K; Nagayama Y; Takeshita A; Namba H; Yamashita S; Niwa M; Nagataki S
    Thyroid; 1996 Jun; 6(3):195-9. PubMed ID: 8837326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Thyreotrophic hypophysial function after surgery for euthyroid goiter or autonomous adenoma].
    Hüfner M; Wahl R; Müller B; Grussendorf M; Röher D
    Endokrinologie; 1980 Jan; 75(1):35-43. PubMed ID: 6768547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Transgenic mouse models. Their interest in thyroid tumors].
    Ledent C; Franc B; Parmentier M
    Arch Anat Cytol Pathol; 1998; 46(1-2):31-7. PubMed ID: 9754358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions.
    Arturi F; Scarpelli D; Coco A; Sacco R; Bruno R; Filetti S; Russo D
    Thyroid; 2003 Apr; 13(4):341-3. PubMed ID: 12804102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Constitutively activating mutations of the thyrotropin receptor and thyroid disease.
    Führer D; Holzapfel HP; Wonerow P; Paschke R
    Eur J Med Res; 1996 Jul; 1(10):460-4. PubMed ID: 9438142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperfunctioning thyroid adenoma and activating mutations in the TSH receptor gene.
    Polak M
    Arch Med Res; 1999; 30(6):510-3. PubMed ID: 10714365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New pathophysiological mechanisms for hyperthyroidism.
    Vassart G
    Horm Res; 1997; 48 Suppl 4():47-50. PubMed ID: 9350447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations of the TSH receptor as cause of congenital hyperthyroidism.
    Schwab KO; Söhlemann P; Gerlich M; Broecker M; Petrykowski W; Holzapfel HP; Paschke R; Grüters A; Derwahl M
    Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():124-8. PubMed ID: 8981019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation.
    Du Villard JA; Wicker R; Crespo P; Russo D; Filetti S; Gutkind JS; Sarasin A; Suárez HG
    Oncogene; 2000 Oct; 19(42):4896-905. PubMed ID: 11039907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations in the mouse TSH receptor equivalent to human constitutively activating TSH receptor mutations also cause constitutive activity.
    Neumann S; Krohn K; Chey S; Paschke R
    Horm Metab Res; 2001 May; 33(5):263-9. PubMed ID: 11440271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism.
    Duprez L; Parma J; Van Sande J; Allgeier A; Leclère J; Schvartz C; Delisle MJ; Decoulx M; Orgiazzi J; Dumont J
    Nat Genet; 1994 Jul; 7(3):396-401. PubMed ID: 7920658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatic mutations in thyroid nodular disease.
    Krohn K; Paschke R
    Mol Genet Metab; 2002 Mar; 75(3):202-8. PubMed ID: 11914031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation.
    Spambalg D; Sharifi N; Elisei R; Gross JL; Medeiros-Neto G; Fagin JA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3898-901. PubMed ID: 8923835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.